Health News Releases

  • Today May 24
Paraffin Bath NP-20
June 28, 2013 10:47
N-Care introduces NP-20 for first time at the ‘2013 Busan International Anti-aging Expo’
Han Seung-beom, the President of N-care. Inc. Ltd. which specialises in medical devices, announced that they will attend the “2013 Busan International Silver Expo” which will be held in Bexco from the
June 27, 2013 09:24
Biohit to Establish Joint Venture in China - Biohit Biotech(Hefei)
Finnish healthcare company Biohit Oyj has agreed to set up a Joint Venture company in China. The Chinese partner to the Joint Venture is Anhui Wisdom-Win Investment Co., Ltd. Official name of the Join
June 26, 2013 17:53
Medical Tourism Association(R) Expands News Website to Heighten Healthcare Awareness, Encourage Patient Engagement
Patients might be tempted to go to any length of the earth to gain access to information that would help them lead a more healthier and productive life if they didn't have it at their finger tips alre
June 26, 2013 15:13
Nanobiotix Announces the Selection of its Second NanoXray Product, NBTX-IV and a Collaboration with the National Cancer Institute for Development
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the selection of a new product for development, NBTX-IV. It
June 24, 2013 16:21
IncellDx Signs Deal With GeneCell Diagnostics to Offer New HPV Technology in India
IncellDx announced today that it has reached an agreement to offer its proprietary laboratory test for the detection of oncogenic HPV E6, E7 mRNA in India. The agreement with GeneCell Diagnostics Pvt.
June 24, 2013 10:20
Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling
In Association of Molecular Pathology v. Myriad, the U.S. Supreme Court struck down BRCA1 and BRCA2 gene patent claims. It is important for the diagnostic community to note that the limits of the Myri
June 17, 2013 09:51
Mayapada Hospital South Jakarta Performs its First Laparoscopic Surgery
Mayapada Hospital South Jakarta performed its first ever laparoscopic surgery to remove fibroids from a woman's body on Wednesday, June 12th. The successful surgery was performed by a team of medical
June 14, 2013 12:00
First Guidelines for Treating Non-Transfusion-Dependent Thalassaemia Introduced at European Haematology Association Meeting
New guidelines released by the Thalassaemia International Federation (TIF) address the Management of Non-Transfusion Dependent Thalassaemias (NTDT) and are a first of their kind in the field of medica
June 13, 2013 15:10
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with Lead Product NBTXR3
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that its lead compound NBTXR3 has received authorizati
June 13, 2013 09:28
IncellDx Signs Deal With Kindstar Global to Offer Novel HPV Technology in China for Cervical Cancer Screening
IncellDx announced today that it has executed an agreement with Kindstar Global, the largest esoteric diagnostic testing service in China, to offer its proprietary laboratory test for the detection of
June 12, 2013 09:32
CanChew Biotechnologies Shipping Large-Scale Product Orders -- Expands Into Wholesale and Distributor Sales of Its CanChew CBD Gum
CanChew Biotechnologies, a Medical Marijuana Inc. (OTC:MJNA) joint venture company, is excited to announce its wholly owned subsidiary CannaGum Marketing Group has opened a new warehouse for CanChew C
June 11, 2013 17:46
Harmony(TM) Prenatal Test Demonstrates Clinical Utility in a General Screening Population
The Harris Birthright Centre for Fetal Medicine today released results from a clinical implementation study (http://onlinelibrary.wiley.com/doi/10.1002/uog.12504/full) on the use of Ariosa Diagnostics
June 04, 2013 15:10
Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-ba
June 03, 2013 14:45
Orsiro From BIOTRONIK, Industry's First Hybrid Drug-Eluting Stent, Performs as Best in Class
Primary end-point results from the BIOFLOW-II Clinical Study demonstrating the non-inferiority of the BIOTRONIK Orsiro Hybrid Drug-Eluting Stent compared to Abbott's XIENCE PRIME™. These results were
May 24, 2013 14:08
BIOTRONIK Announces Completion of Enrollment in IMPACT Study to Investigate Stroke Risk Reduction in Patients With Atrial Fibrillation
BIOTRONIK, a leading manufacturer of innovative medical technology, announced today that enrollment has been completed for the highly anticipated IMPACT study. The study aims to investigate whether th
May 21, 2013 23:00
Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today presented positive safety and efficacy results from its large
May 16, 2013 22:00
Medical Marijuana Inc., Posts 1st Quarter Audited Financial and Disclosure Statements; Net Income Exceeds Quarterly Projections
Medical Marijuana Inc. (OTC:MJNA) is pleased to inform shareholders that it has completed and posted its 1st Quarter 2013 Audited Financial Statements and Corporate Disclosure. The disclosure can be f
May 15, 2013 18:29
Invivoscribe Prevails in German District Court (FLT3 Patent Infringement Action)
MLL Münchner Leukämielabor GmbH (“MLL”) Laboratories has been found guilty of patent infringement in a matter involving FLT3 testing patent rights licensed exclusively to Invivoscribe Technologies, In
May 15, 2013 09:52
Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has been selected for addition to the NASDAQ Biotechnolog
Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results
May 10, 2013 09:43
Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the first quarter en
May 09, 2013 10:53
EasyMed Reports Publication of Results of a Large-Scale Trial With the University Hospital of Geneva in the Peer-Reviewed Journal BMC Health Service Research
EasyMed Services Inc. (CNSX:EZM)(PINKSHEETS:EMYSF)(MUN:EY6) (“EasyMed” or the “Company”) announces that the report of a large-scale study conducted by the University Hospital of Geneva, using EasyMed'
May 02, 2013 18:00
GlobalMed, International Virtual e-Hospital Foundation, and ITF Entering Phase II of Telemedicine Implementation in Cape Verde
GlobalMed®—the worldwide leader in real-time healthcare delivery systems—along with the International Trust Fund Enhancing Human Security (ITF), a non-profit organization founded by the Republic of Sl
April 22, 2013 12:00
Medical Marijuana Inc.'s Dixie Botanicals Brand Announces New Exciting Products and a Consumer Friendly Mobile App
Medical Marijuana Inc. (OTC:MJNA), a leading hemp industry innovator, announced that its portfolio company, Red Dice Holdings, LLC brand Dixie Botanicals is rolling out three new exciting offerings.
April 17, 2013 09:59
Medical Marijuana Inc.'s Dixie Elixirs Brand to Co-Sponsor Premiere of Snoop Lion Movie “Reincarnated” During 4/20 Week
Medical Marijuana Inc. (OTC:MJNA), a leading hemp industry innovator, announced that its portfolio company, Red Dice Holdings, LLC brand Dixie Elixirs and Edibles, has completed negotiations with The
April 17, 2013 09:48
Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock
Synergy Pharmaceuticals Inc.(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its underwritten public offering of 16,375,000 shares of
25 per page50 per page75 per page100 per page